HEMISPHERX BIOPHARMA | 0,166 Euro | -0,018 -9,78 % | |
| WKN: 906543 ISIN: US42366C1036 Ticker-Symbol: HXB | Frankfurt | 25.05.12 | 17:49 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 14.03. | Hemispherx Biopharma FY11 Loss Narrows | 37 | AFX News | |
| WASHINGTON (dpa-AFX) - Hemispherx Biopharma (HEB) reported a full-year net
loss of $9.0 million or $0.07 per share, narrower than last year's loss of $13.1
million or $0.10 per share.This... Mehr lesen zu: Hemispherx Biopharma FY11 Loss Narrows | ||||
| 17.01. | Hemispherx Biopharma Receives Two US Patents For Alferon LDO | 24 | AFX News | |
| HONG KONG (dpa-AFX) - Hemispherx Biopharma, Inc. (HEB) announced today the
granting of two new United States Patents for the use of Alferon LDO. Hemispherx
Biopharma, Inc. (HEB) announced... Mehr lesen zu: Hemispherx Biopharma Receives Two US Patents For Alferon LDO | ||||
| 17.01. | Hemispherx (HEB) Receives Two New Patents for Alferon(R) LDO | - | StreetInsider.com | |
| 11.01. | FDA Grants Hemispherx Extension In NDA For Treatment Of Chronic Fatigue Syndrome | 37 | AFX News | |
| WASHINGTON (dpa-AFX) - Hemispherx Biopharma Inc. (HEB) announced that the
Food and Drug Administration granted an extension for the Company to modify its
New Drug Application or 'NDA' in... Mehr lesen zu: FDA Grants Hemispherx Extension In NDA For Treatment Of Chronic Fatigue Syndrome | ||||
| 11.01. | Hemispherx Biopharma (HEB) Gets Extension from FDA for CFS NDA Modification | - | StreetInsider.com | |
| 09.12. | Hemispherx Biopharma Gets Stockholder Approval For Increasing Authorized Shares | 79 | AFX News | |
| WASHINGTON (dpa-AFX) - Hemispherx Biopharma, Inc. (HEB) Thursday said its
proposal to increase the number of authorized shares of common stock to 350
million from 200 million was passed... Mehr lesen zu: Hemispherx Biopharma Gets Stockholder Approval For Increasing Authorized Shares | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| GENEREX BIOTECHNOLOGY CORPORATION | 0,069 | +2,99 % | Generex Augments Antigen Express Scientific Advisory Board |
| EVOTEC AG | 2,198 | +0,23 % | Evotec: Wichtige Hürde im Blickpunkt |
| YM BIOSCIENCES | 1,720 | +10,82 % | YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012 |
| MIV THERAPEUTICS INC | 0,071 | 0 % | EANS-News: MIV Therapeutics Inc. / NEUESTE MELDUNG ZUM VERKAUF DER INDISCHEN SPARTE |
| AGENNIX AG | 1,720 | +1,18 % | ERS: AGENNIX AG / 3-Monatsbericht 2012 |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
